


### Amendments to the claims

#### Listing of claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A compound of formula (I):



wherein:

one of Z<sub>1</sub>, Z<sub>2</sub>, Z<sub>3</sub>, Z<sub>4</sub> and Z<sub>5</sub> is N, one is CR<sup>1a</sup> and the remainder are CH, or CH, or  
one or two of Z<sub>1</sub>, Z<sub>2</sub>, Z<sub>3</sub>, Z<sub>4</sub> and Z<sub>5</sub> are independently CR<sup>1a</sup> and the remainder are  
CH;

R<sup>1</sup> and R<sup>1a</sup> are independently hydrogen; hydroxy; (C<sub>1-6</sub>)alkoxy unsubstituted or substituted by (C<sub>1-6</sub>)alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C<sub>1-6</sub>)alkyl, acyl or (C<sub>1-6</sub>)alkylsulphonyl groups, CONH<sub>2</sub>, hydroxy, (C<sub>1-6</sub>)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C<sub>1-6</sub>)alkylsulphonyloxy; (C<sub>1-6</sub>)alkoxy-substituted(C<sub>1-6</sub>)alkyl; halogen; (C<sub>1-6</sub>)alkyl; (C<sub>1-6</sub>)alkylthio; trifluoromethyl; trifluoromethoxy; nitro; cyano; azido; acyl; acyloxy; acylthio; (C<sub>1-6</sub>)alkylsulphonyl; (C<sub>1-6</sub>)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C<sub>1-6</sub>)alkyl, acyl or (C<sub>1-6</sub>)alkylsulphonyl groups;

provided that when  $Z_1$ ,  $Z_2$ ,  $Z_3$ ,  $Z_4$  and  $Z_5$  are  $CR^{1a}$  or CH, then  $R^1$  is not hydrogen;

$W_1$ ,  $W_2$ ,  $W_3$  and  $W_4$  are each independently selected from N or  $CR^3$ ;

each  $R^3$  is independently selected from:

hydrogen; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido;  
acyl; acyloxy; acylthio; amino, mono- and di-( $C_{1-6}$ )alkylamino; and substituted and  
unsubstituted ( $C_{1-6}$ )alkoxy, ( $C_{1-6}$ )alkyl, ( $C_{3-7}$ )cycloalkyl, aminocarbonyl,  
( $C_{1-6}$ )alkylthio, ( $C_{1-6}$ )alkylsulphonyl, and ( $C_{1-6}$ )alkylsulphoxide;

A is  $(CRR)_n$ ;

B is  $(CRR)_m$ , C=O, or  $SO_2$ ;

n is 1 or 2;


m is 1 or 2;

provided that when n is 1, m is 2; when n is 2, m is 1; and when B is C=O or  $SO_2$   
then n is 2;

each R is independently selected from

hydrogen; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl;  
acyloxy; acylthio; amino, mono- and di-( $C_{1-6}$ )alkylamino; and substituted and  
unsubstituted ( $C_{1-6}$ )alkoxy, ( $C_{1-6}$ )alkyl, ( $C_{3-7}$ )cycloalkyl, aminocarbonyl,  
( $C_{1-6}$ )alkylthio, ( $C_{1-6}$ )alkylsulphonyl, and ( $C_{1-6}$ )alkylsulphoxide;

$R^2$  is a substituted or unsubstituted bicyclic heterocyclic ring system of formula (A):



containing up to four heteroatoms in each ring in which

ring (a) is substituted or unsubstituted pyridine and ring (b) is substituted or  
unsubstituted non-aromatic;

$X^1$  is C;

$X^2$  is N or  $CR^4$ ;

$X^3$  and  $X^4$  are C;

Y<sup>1</sup> is a 2 atom linker group each atom of which is independently selected from N and CR<sup>4</sup>;

Y<sup>2</sup> is a 4 atom linker group having S bonded to X<sup>4</sup> and NHCO bonded via N to X<sup>3</sup> in which the other atom is CR<sup>4</sup>R<sup>5</sup>; and

each R<sup>4</sup> and R<sup>5</sup> is independently selected from: hydrogen; (C<sub>1-4</sub>)alkylthio; halo; carboxy(C<sub>1-4</sub>)alkyl; halo(C<sub>1-4</sub>)alkoxy; halo(C<sub>1-4</sub>)alkyl; (C<sub>1-4</sub>)alkyl; (C<sub>2-4</sub>)alkenyl; (C<sub>1-4</sub>)alkoxycarbonyl; formyl; (C<sub>1-4</sub>)alkylcarbonyl; (C<sub>2-4</sub>)alkenyloxycarbonyl; (C<sub>2-4</sub>)alkenylcarbonyl; (C<sub>1-4</sub>)alkylcarbonyloxy; (C<sub>1-4</sub>)alkoxycarbonyl(C<sub>1-4</sub>)alkyl; hydroxy; hydroxy(C<sub>1-4</sub>)alkyl; mercapto(C<sub>1-4</sub>)alkyl; (C<sub>1-4</sub>)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl **[[is]]** optionally substituted by (C<sub>1-4</sub>)alkoxycarbonyl, (C<sub>1-4</sub>)alkylcarbonyl, (C<sub>2-4</sub>)alkenyloxycarbonyl, (C<sub>2-4</sub>)alkenylcarbonyl, (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl and optionally further substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl; (C<sub>2-6</sub>)alkenyl; (C<sub>1-4</sub>)alkylsulphonyl; (C<sub>2-4</sub>)alkenylsulphonyl; **[[or]]** aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl; aryl; aryl(C<sub>1-4</sub>)alkyl; and aryl(C<sub>1-4</sub>)alkoxy; or R<sup>4</sup> and R<sup>5</sup> may together represent oxo; and

~~each R<sup>6</sup> is independently hydrogen; trifluoromethyl; (C<sub>1-4</sub>)alkyl unsubstituted or substituted by hydroxy, (C<sub>1-6</sub>)alkoxy, (C<sub>1-6</sub>)alkylthio, halo or trifluoromethyl; (C<sub>2-4</sub>)alkenyl; aryl; aryl(C<sub>1-4</sub>)alkyl; arylcarbonyl; heteroarylcarbonyl; (C<sub>1-4</sub>)alkoxycarbonyl; (C<sub>1-4</sub>)alkylcarbonyl; formyl; (C<sub>1-6</sub>)alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C<sub>1-4</sub>)alkoxycarbonyl, (C<sub>1-4</sub>)alkylcarbonyl, (C<sub>2-4</sub>)alkenyloxycarbonyl, (C<sub>2-4</sub>)alkenylcarbonyl, (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl and optionally further substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl;~~

wherein the term acyl means a formyl or a (C<sub>1-6</sub>)alkylcarbonyl group;

or a pharmaceutically acceptable salt thereof.

2. (Currently amended) A compound according to claim 1 wherein  $Z_5$  is CH or N,  $Z_3$  is CH or CF and  $Z_1$ ,  $Z_2$  and  $Z_4$  are each CH, ~~or  $Z_4$  is N,  $Z_3$  is CH or CF and  $Z_2$ ,  $Z_4$  and  $Z_5$  are each CH.~~

3. (Original) A compound according to claim 1 wherein  $R^1$  is methoxy and  $R^{1a}$  is H or when  $Z_3$  is  $CR^{1a}$  it may be C-F.

4. (Currently amended) A compound according to claim 1 wherein  $W_1$ - $W_4$  are independently  $CR^3$ :

~~a)  $W_1$ - $W_4$  are independently  $CR^3$ ;~~

~~b)  $W_1$ ,  $W_3$  and  $W_4$  are N and  $W_2$  is  $CR^3$ ;~~

~~c)  $W_2$  is N and  $W_1$ ,  $W_3$  and  $W_4$  are independently  $CR^3$ ;~~

~~d)  $W_3$  is N and  $W_1$ ,  $W_2$  and  $W_4$  are independently  $CR^3$ ; or~~

~~e)  $W_4$  is N and  $W_1$ - $W_3$  are independently  $CR^3$ .~~

5. (Original) A compound according to claim 1 wherein  $R^3$  is independently selected from hydrogen, substituted and unsubstituted ( $C_{1-6}$ )alkoxy, and  $NH_2$ .

6. (Original) A compound according to claim 1 wherein R is independently selected from hydrogen, substituted and unsubstituted ( $C_{1-6}$ )alkyl,  $CONH_2$ ,  $COOH$ , hydroxy, halogen, and substituted and unsubstituted ( $C_{1-6}$ )alkoxy.

7. Canceled.

8. (Previously presented) A compound according to claim 1 wherein  $R^2$  is selected from 4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one-6-yl and 1*H*-pyrido[3,2-*b*][1,4]thiazin-2-one-7-yl.

9. (Currently amended) A compound according to claim 1 which is:

6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

7-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-1*H*-pyrido[3,2-*b*][1,4]thiazin-2-one;

6-({2-[4-(6,8-difluoroquinolin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[4-(8-Fluoro-6-methoxyquinolin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[5-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-2-yl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

*N*-(2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide; ~~and~~ or

*N*-(2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide;

or a pharmaceutically acceptable salt thereof.

10. (Original) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

11. (Currently amended) A method of treating bacterial infections due to an organism selected from *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Enterococcus faecalis*, *Enterococcus faecium*, *Haemophilus influenzae*, *E. coli*, and *Moraxella catarrhalis* in mammals which comprises the administration to a mammal in need thereof an effective amount of a compound according to claim 1.

12. (Previously presented) A compound according to claim 1 wherein X<sup>2</sup> is N and Y<sup>1</sup> is a 2 atom linker group each atom of which is independently CR<sup>4</sup>.

13. (New) A method according to claim 11 wherein the mammal is a human.

14. (New) A compound according to claim 1 wherein Z<sub>1</sub> is N, Z<sub>3</sub> is CH or CF and Z<sub>2</sub>, Z<sub>4</sub> and Z<sub>5</sub> are each CH.

15. (New) A compound according to claim 1 wherein W<sub>1</sub>, W<sub>3</sub> and W<sub>4</sub> are N and W<sub>2</sub> is CR<sup>3</sup>.

16. (New) A compound according to claim 1 wherein  $W_2$  is N and  $W_1$ ,  $W_3$  and  $W_4$  are independently  $CR^3$ .
17. (New) A compound according to claim 1 wherein  $W_3$  is N and  $W_1$ ,  $W_2$  and  $W_4$  are independently  $CR^3$ .
18. (New) A compound according to claim 1 wherein  $W_4$  is N and  $W_1$ - $W_3$  are independently  $CR^3$ .
19. (New) A compound according to claim 1 wherein  $R^4$  is hydrogen, fluorine or nitro and  $R^5$  is hydrogen.
20. (New) A compound according to claim 1 wherein R is hydrogen.
21. (New) A compound according to claim 1 wherein  $R^3$  is hydrogen.